ArticleAntibiotics (Basel, Switzerland)2018
First Description of Colistin and Tigecycline-Resistant
Article in Antibiotics (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Carbapenem-ResistantMicroorganisms · 2025Review
- Tackling Carbapenem Resistance and the Imperative for One Health Strategies-Insights from the Portuguese Perspective.Antibiotics (Basel, Switzerland) · 2024Review
- InvasiveFrontiers in medicine · 2024Article
- CRISPR-Based Gene Editing inPharmaceuticals (Basel, Switzerland) · 2023Review
- Antimicrobial Resistance in Romania: Updates on Gram-Negative ESCAPE Pathogens in the Clinical, Veterinary, and Aquatic Sectors.International journal of molecular sciences · 2023Review
- Penicillin Binding Protein 7/8 Is a Potential Drug Target in Carbapenem-Resistant Acinetobacter baumannii.Antimicrobial agents and chemotherapy · 2023Article
- Evasion of Antimicrobial Activity inInternational journal of molecular sciences · 2022Review
- The Gram-Negative Bacilli Isolated from Caves-International journal of environmental research and public health · 2022Review
- Whole-Genome Sequencing Enables Molecular Characterization of Non-Clonal Group 258 High-Risk Clones (ST13, ST17, ST147 and ST307) among Carbapenem-ResistantMicroorganisms · 2022Article
- First Outbreak of NDM-1-ProducingMicroorganisms · 2022Article
- Article
- An Update on Wastewater Multi-Resistant Bacteria: Identification of Clinical Pathogens Such asMicroorganisms · 2021Article
- Bacteria Broadly-Resistant to Last Resort Antibiotics Detected in Commercial Chicken Farms.Microorganisms · 2021Article
- Genomic Epidemiology of Carbapenemase ProducingMicroorganisms · 2020Article
- Multicenter Evaluation of the Xpert Carba-R Assay for Detection and Identification of Carbapenemase Genes in Sputum Specimens.Journal of clinical microbiology · 2020Article
- The Current Burden of Carbapenemases: Review of Significant Properties and Dissemination among Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2020Review
- Insights intoAntibiotics (Basel, Switzerland) · 2020Review
- Multidrug-resistant Klebsiella pneumoniae: genetic diversity, mechanisms of resistance to polymyxins and clinical outcomes in a tertiary teaching hospital in Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2019Article
- Community- and Hospital-AcquiredMicroorganisms · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herein, we describe a case report of carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.